Reproductive Embryo Editing: Attending to Justice
By Inmaculada De Melo-Martín,
The Hastings Center Report
| 08. 22. 2022
Advances in genome editing technologies allow scientists to add, remove, or alter genetic material at particular locations in the human genome. Genome editing of somatic cells offers great promise in the prevention and treatment of various human diseases. But these technologies could also be used to modify gametes and embryos. Some commentators defend gene editing for reproductive purposes on the ground that it would allow people who are at risk of transmitting genetic diseases to their offspring to have healthy and genetically related children.
Using gene editing in this way would require further research. The technology still presents problems involving off-target effects and reliability. Researchers must improve delivery to desired tissues and control of immunogenic reactions. Yet I argue here that, if we accept certain background claims about justice, accepting the goal of helping people have healthy and genetically related children should commit one to rejecting the investment of social resources into further development of reproductive embryo editing.
Considerations of justice are relevant to questions regarding the development of reproductive embryo editing for several reasons. First, decisions about research-funding priorities involve...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...